The effect of vitamin D on oral lichen planus
- Conditions
- Oral lichen planus.Lichen planus
- Registration Number
- IRCT20171017036835N2
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
1. Patients with erosive-atrophic oral lichen planus with confirmation of clinical diagnosis and histopathology confirmation. 2. Patients have not used any systemic or topical drug for the treatment of lichen planus over the past 2 weeks. 3. In the past 3 months, they have not used any vitamin supplements. 4. Patients aged 18-80 years old were considered. 5. People with vitamin D deficiency or insufficiency (25 (OH) D <30 mg / dl). 6. Patients with grade 2 to 5 Thongprosam criteria will enroll in this study.
1. People who have been diagnosed with , mild to severe dysplasia. 2. Calcium levels above 10 mg / dl, phosphorus less than 2.5 mg / dl (rejection of hyperparathyroidism) 3. lichenoid reaction. 4. Patients who do not have the necessary co-operation or attending the control sessions. 5. Pregnant women 6. Metabolic bone diseases such as: osteomalacia and primary hyperparathyroidism (with endocrinologist confirmation) 7. Patient with a history of severe renal-hepatic dysfunction 8. Chronic inflammatory disease in addition to lichen planus 9. If you have a history of being allergic to vitamin D supplements (itching, inflammation or redness in the skin and cramps, then using the supplementation of this vitamin) 10. Patients who use barbiturates and phenytoin. 11. Patients with granulomatous diseases, including sarcoidosis 12. History of malabsorption or chronic pancreatitis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Burning and pain. Timepoint: every 2 week for 2 months. Method of measurement: visual analogue scale.;Size and severity of lesion. Timepoint: every 2 week for 2 months. Method of measurement: thongprasom.
- Secondary Outcome Measures
Name Time Method Cytokines TNF-a and IL-6. Timepoint: before treatment and 2 month later. Method of measurement: ELISA.